- Home
- PINE vs FENC Comparison
PINE vs FENC Comparison
Compare PINE & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | FENC |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 230.8M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PINE | FENC |
|---|---|---|
| Price | $19.18 | $9.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.10 | $14.50 |
| AVG Volume (30 Days) | 161.3K | ★ 365.1K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | 0.01 |
| Revenue | ★ $60,532,000.00 | $44,642,000.00 |
| Revenue This Year | $18.63 | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ $321.83 | $986.50 |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $13.10 | $5.65 |
| 52 Week High | $20.80 | $10.45 |
Technical Indicators
Market Signals| Indicator | PINE | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 74.32 |
| Support Level | $18.72 | $7.45 |
| Resistance Level | $19.98 | $10.18 |
| Average True Range (ATR) | 0.37 | 0.65 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 42.79 | 84.86 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.